Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire Will Cut Manufacturing Sites As It Looks For More Baxalta Synergies

Executive Summary

Shire had a combined 17 manufacturing plants after the Baxalta merger, but plans to cut that to a total of 12. Manufacturing issues hit sales of its HAE drug Cinryze in the third quarter, and the firm is losing Lialda sales faster than expected.

Advertisement

Related Content

Shire Touts Ongoing Xiidra Growth, Targets Increased Medicare Access
Shire Sees Another Way To Compete With CSL Behring In HAE With New Version Of Cinryze
Shire's Ornskov On Goals And Accomplishments One Year After Baxalta Merger
Shire’s Ornskov Says Baxalta Integration on Track, Ups Synergies Forecast

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099769

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel